Fiera Capital Corp Acquires Shares of 605,527 Insmed Incorporated (NASDAQ:INSM)

Fiera Capital Corp purchased a new stake in Insmed Incorporated (NASDAQ:INSM) in the 2nd quarter, HoldingsChannel.com reports. The fund purchased 605,527 shares of the biopharmaceutical company’s stock, valued at approximately $40,570,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. New York State Common Retirement Fund boosted its stake in shares of Insmed by 7.3% during the fourth quarter. New York State Common Retirement Fund now owns 56,131 shares of the biopharmaceutical company’s stock worth $1,739,000 after buying an additional 3,841 shares during the period. Victory Capital Management Inc. lifted its position in Insmed by 21.4% during the 4th quarter. Victory Capital Management Inc. now owns 18,797 shares of the biopharmaceutical company’s stock worth $583,000 after acquiring an additional 3,311 shares during the period. Charles Schwab Investment Management Inc. grew its stake in shares of Insmed by 2.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,128,436 shares of the biopharmaceutical company’s stock valued at $34,970,000 after purchasing an additional 28,629 shares during the last quarter. E Fund Management Co. Ltd. grew its stake in shares of Insmed by 22.3% in the 4th quarter. E Fund Management Co. Ltd. now owns 17,178 shares of the biopharmaceutical company’s stock valued at $532,000 after purchasing an additional 3,130 shares during the last quarter. Finally, Calton & Associates Inc. acquired a new position in shares of Insmed in the fourth quarter valued at approximately $248,000.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on INSM shares. Guggenheim lifted their price objective on shares of Insmed from $70.00 to $95.00 and gave the company a “buy” rating in a research report on Tuesday, July 9th. UBS Group lifted their target price on shares of Insmed from $78.00 to $84.00 and gave the company a “buy” rating in a report on Friday, August 9th. Mizuho increased their price target on shares of Insmed from $36.00 to $82.00 and gave the stock a “buy” rating in a report on Friday, June 7th. Barclays raised their price objective on shares of Insmed from $40.00 to $63.00 and gave the company an “overweight” rating in a research report on Wednesday, May 29th. Finally, TD Cowen boosted their target price on Insmed from $75.00 to $98.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. One analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $79.19.

Insmed Stock Down 4.1 %

INSM stock opened at $73.31 on Wednesday. The company has a debt-to-equity ratio of 25.05, a current ratio of 2.71 and a quick ratio of 2.53. Insmed Incorporated has a 12 month low of $21.92 and a 12 month high of $80.53. The firm has a market capitalization of $10.89 billion, a PE ratio of -14.02 and a beta of 1.16. The company’s 50 day simple moving average is $73.53 and its 200-day simple moving average is $48.09.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($1.94) EPS for the quarter, missing analysts’ consensus estimates of ($1.22) by ($0.72). The company had revenue of $90.34 million during the quarter, compared to analyst estimates of $87.95 million. During the same quarter in the prior year, the firm posted ($1.78) earnings per share. The firm’s revenue was up 17.0% on a year-over-year basis. Equities analysts expect that Insmed Incorporated will post -5.42 earnings per share for the current fiscal year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.